Reactivity of chloro(N-methyliminodiacetato)palladium(II) and chloro(pyridyl-2,6-dicarboxylato)palladium(II) complexes with purine based 5′-nucleotides and glutathione: antitumor activity of platinum(II)-analogs

The interaction of [PdII(mida)(Cl)]− (1) (mida2− = N-methyliminodiacetate) and [PdII(pydc)(Cl)]− (2) (pydc2− = pyridyl-2,6-dicarboxylate) with adenosine-5′-monophosphate (AMP), inosine-5′-monophosphate (IMP) and glutathione (GSH) was studied kinetically as a function of [L] (L = AMP, IMP, GSH) and [Cl−] and temperatures (10–35 °C) at pH 4.0. The kinetic results suggest that the reaction of 1 and 2 with the 5′-nucleotides (AMP, IMP) is characterized by the hydrolysis of chloro-complexes followed by the aquo-substitution with purine based 5′-nucleotides through its N7 atom. The reaction of 1 and 2 with GSH takes place through the direct chloride replacement with GSH. Kinetic data and activation parameters are interpreted in terms of an associative mechanism and discussed in reference to the data reported earlier. The [PtII(mida)(Cl)]− (3) and [PtII(pydc)(Cl)]− (4) complexes were prepared and allowed to interact with AMP and IMP and their reaction products were characterized by 1H NMR studies. The antitumor activity of 3 and 4 was examined against MCF-7 (breast cancer), NCI-H460 (lung cancer) and SF-268 (CNS) cell lines.

Graphical abstractThe [PdII(mida)(Cl)]− (1) binds DNA fragments at a higher rate than glutathione (GSH) The platinum analogs inhibit cell proliferation of MCF-7 (breast cancer), NCI-H460 (lung cancer) and SF-268 (CNS) cell lines.Figure optionsDownload full-size imageDownload as PowerPoint slide